Skin-to-tumor Distance Predicts Treatment Failure of T1A Renal Cell Carcinoma Following Percutaneous Cryoablation - PubMed (original) (raw)

Multicenter Study

doi: 10.1016/j.urology.2017.06.026. Epub 2017 Jun 23.

Zhamshid Okhunov 1, Kamaljot Kaler 1, Ramy F Youssef 1, Rahul Dutta 1, Arkadiy Palvanov 2, Paras Shah 2, Kathryn Osann 1, David N Siegel 2, Igor Lobko 2, Louis Kavoussi 2, Ralph V Clayman 1, Jaime Landman 3

Affiliations

Multicenter Study

Skin-to-tumor Distance Predicts Treatment Failure of T1A Renal Cell Carcinoma Following Percutaneous Cryoablation

Simone L Vernez et al. Urology. 2017 Oct.

Abstract

Objective: To determine the impact of skin-to-tumor (STT) distance on the risk for treatment failure following percutaneous cryoablation (PCA).

Methods: We retrospectively reviewed patients who underwent PCA with documented T1a recurrent renal cell carcinoma (RCC) at 2 academic centers between 2005 and 2015. Patient demographics, tumor characteristics, and perioperative and postoperative course variables were collected. Additionally, we measured the STT distance by averaging the distance from the skin to the center of the tumor at 0°, 45°, and 90° on preoperative computed tomography imaging.

Results: We identified 86 patients with documented T1a RCC. The mean age at the time of surgery was 69 years (range: 37-91 years), and the mean tumor size was 2.7 cm (range: 1.0-4.0 cm). With a mean follow-up of 24 months (range: 3-63 months), 11 (12.8%) treatment failures occurred. Patients with treatment failure had significantly higher mean STT distance than those without: 11.0 cm (range: 6.3-20.1 cm) compared to 8.4 cm (range: 4.4-15.2 cm), respectively (P = .002). STT distance was an independent predictor of treatment failure (odds ratio: 1.32, 95% confidence interval: 1.04-1.69, P = .029). STT distance greater than 10 cm had a fourfold increased risk of tumor treatment failure (odds ratio: 4.43, 95% confidence interval: 1.19-16.39, P = .018). Tumor size, R.E.N.A.L. Nephrometry score, and number of cryoprobes placed were not associated with treatment failure.

Conclusion: STT, an easily measured preoperative variable, may inform the risk of RCC treatment failure following PCA.

Copyright © 2017 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure: The authors declare that they have no relevant financial interests.

Figures

Figure 1.

Figure 1.

Axial imaging demonstrating presence of renal tumor and method of measuring skin-to-tumor at 0°, 45°, and 90°.

References

    1. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67:519–530. -PubMed
    1. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol. 2006;176:2397–2400. -PubMed
    1. Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67:252–259. -PubMed
    1. Long CJ, Kutikov A, Canter DJ, et al. Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? BJU Int 2011;107:1376–1380. -PubMed
    1. Sewell P, Shingleton WB. Five-year treatment success and survival of patients treated with percutaneous MRI guided and monitored renal cell carcinoma cryoablation. BJU Int. 2004;94:106. (Abstract).

Publication types

MeSH terms

LinkOut - more resources